• Vicenti et al assessed the

  2022-10-12

  

  Vicenti et al. [38] assessed the prevalence of HCV NS3/4A PI resistance mutations in HCV genotype 1-infected PI-naïve individuals, including 66 subjects coinfected with HCV/HIV. They found that 19.3% of isolates have at least one mutation related to PI resistance, and the HCV PI resistance mutations

• Substrate affinity and specificity can

  2022-10-12

  

  Substrate affinity and specificity can be enhanced by docking interactions, in which regions distal to the site of GSK1904529A bind to grooves, pockets, or surfaces outside of the kinase catalytic cleft 1, 2, 5, 6. Like catalytic site interactions, docking interactions can involve recognition of sh

• br Modulators of the GUCY

  2022-10-12

  

  Modulators of the GUCY2C/cGMP/PDEs signaling pathways for CRC prevention and therapy (pre-clinical and clinical development) Several modulators of the GUCY2C/cGMP/PDEs signaling pathways, including GUCY2C agonists and PDEs inhibitors, have been developed and explored as chemopreventive agents for

• br Conflict of interest br Acknowledgement br Exposure

  2022-10-12

  

  Conflict of interest Acknowledgement Exposure to tobacco smoke in early life has been found to increase the risk of developing asthma and lung function deficits in adolescence and adulthood., , , , However, not all children exposed to tobacco smoke in early life develop asthma, which sugges

• br GSK Glycogen synthase kinase GSK is a

  2022-10-12

  

  GSK-3 Glycogen synthase kinase-3 (GSK-3) is a ubiquitous serine/threonine kinase that is involved in multiple signaling pathways that are crucial for cellular metabolism and proliferation (Doble and Woodgett, 2003, Frame and Cohen, 2001, Grimes and Jope, 2001, Woodgett, 1990). GSK-3 is known to d

• The differential tissue and ligand dependent signaling

  2022-10-12

  

  The differential tissue- and ligand-dependent signaling described here has important implications for the therapeutic potential of synthetic GPR109A agonists for the treatment of atherosclerosis. The failure of MK-0354, a biased, partial GPR109A agonist, to activate signaling pathways upstream of va

• The two competitive bivalent GlxI inhibitors polyBHG nM and

  2022-10-12

  

  The two competitive bivalent GlxI inhibitors polyBHG2-62 (=1nM) and polyBHG2-54 (=0.3nM) () were designed based on the transition-state analog -(-bromophenyl--hydroxycarbamoyl) glutathione (BHG) by an examination of the X-ray crystal structure of human GlxI in complex with one CHG at each active sit

• We also observed a significantly

  2022-10-12

  

  We also observed a significantly higher SLC10A1 gene expression and NTCP protein level among metastatic individuals vs. donor livers. Na+/taurocholate co-transporting polypeptide (NTCP), which is expressed on the basolateral membrane of hepatocytes and is primarily responsible for the uptake of bile

• We also demonstrated that inhibition of NAAG hydrolysis to

  2022-10-12

  

  We also demonstrated that inhibition of NAAG hydrolysis to suppress glutamate production through a GCPII inhibitor is a viable target for cancer therapy. GCPII is also known as N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) or NAAG peptidase (Pinto et al., 1996), and its increased express

• The third generation cephalosporin antibiotics can cross

  2022-10-12

  

  The third-generation cephalosporin Orlistat can cross the blood brain barrier (BBB) [94]. In addition, several studies have shown that CEF can also cross the BBB [95,96] through a facilitated transport process [95]. However, due to the fact that CEF has poor bioavailability when taken orally, CEF m

• To directly address whether pharmacological attenuation

  2022-10-12

  

  To directly address whether pharmacological attenuation of physiological GIP provides therapeutic benefits in obese mice, we pursued a selective long-acting antagonist to complement the work we report on GIPR agonism. We report a GIP analog of sufficient aqueous solubility that employs a shortened N

• We tested formyl MYVKWPWYVWL which we had previously shown

  2022-10-11

  

  We tested formyl-MYVKWPWYVWL, which we had previously shown to have essentially identical Kis for W190/N192, R190/K192 and R190/N190 [8] of 130 nM, for its ability to downregulate surface receptor (Fig. 5A). R190/K192 exhibited the lowest EC50 of 44±4 nM about 3 fold below the observed Ki and a maxi

• Fas ligand FasL the natural ligand

  2022-10-11

  

  Fas ligand (FasL), the natural ligand of Fas, can interact with Fas and thus induce cell apoptosis through the cascade of death signal in various cell types [8]. Additionally, Fas, which is a member of the tumor necrosis factor (TNF) receptor superfamily and death receptor family, is one kind of tra

• KDM D also known as JARID D or SMCY

  2022-10-10

  

  KDM5D (also known as JARID1D or SMCY) is encoded on the Y chromosome and until now it has been implicated in prostate cancer invasion and metastasis [42], spermatogenesis [43], and sex-specific tissue transplantation rejection [44]. KDM5D acts as a direct epigenetic modulator, and as one of the four

• A second H R antagonist with benzamide based

  2022-10-10

  

  A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass

16755 records 416/1117 page Previous Next First page 上5页 416417418419420 下5页 Last page